Data gathered: December 26
Alternative Data for Novartis
About Novartis
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue.
| Price | $98.35 |
| Target Price | Sign up |
| Volume | 337,380 |
| Market Cap | $197B |
| Year Range | $94.36 - $120.89 |
| Dividend Yield | 3.85% |
| PE Ratio | 17.16 |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?December 23 - Yahoo Entertainment |
|
 |
Novartis AG (NYSE:NVS) Receives Consensus Recommendation of “Reduce” from AnalystsDecember 23 - ETF Daily News |
|
Tidal Investments LLC Has $653,000 Position in Novartis AG (NYSE:NVS)December 22 - ETF Daily News |
 |
Some 330 jobs hit as Novartis closes Morphosys, WiWo reportsDecember 19 - Yahoo Entertainment |
 |
Novartis shutters MorphoSys sites, lays off staffDecember 18 - Yahoo |
 |
BioAge and Novartis seek drug targets for ageing-related diseasesDecember 18 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 12.8B | 3.3B | 9.52B | 3.19B | 5.62B | 2.060 |
| Q2 '24 | 12.5B | 3.22B | 9.3B | 3.25B | 5.09B | 1.970 |
| Q1 '24 | 11.8B | 3.13B | 8.7B | 2.69B | 4.94B | 1.800 |
| Q4 '23 | 11.8B | 3.02B | 8.75B | 8.48B | 4.18B | 1.530 |
| Q3 '23 | 12.1B | 3.12B | 8.98B | 1.76B | 4.89B | 1.830 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Sheldon Whitehouse Democrat |
May 20, 24 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
Mar 6, 24 | Buy | $1K - $15K |
| Sheldon Whitehouse Democrat |
Oct 17, 23 | Buy | $15K - $50K |
Read more about Novartis (NVS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novartis?
The Market Cap of Novartis is $197B.
What is Novartis' PE Ratio?
As of today, Novartis' PE (Price to Earnings) ratio is 17.16.
What is the current stock price of Novartis?
Currently, the price of one share of Novartis stock is $98.35.
How can I analyze the NVS stock price chart for investment decisions?
The NVS stock price chart above provides a comprehensive visual representation of Novartis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novartis shares. Our platform offers an up-to-date NVS stock price chart, along with technical data analysis and alternative data insights.
Does NVS offer dividends to its shareholders?
Yes, Novartis (NVS) offers dividends to its shareholders, with a dividend yield of 3.85%. This dividend yield represents Novartis' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novartis in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novartis?
Some of the similar stocks of Novartis are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.